Covalon to Exhibit at the World Union of Wound Healing Societies in Florence, Italy
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced
that it will be exhibiting its advanced wound care line up of products at the 5th World Congress of the World Union of Wound
Healing Societies (“WUWHS”) to be held in Florence from the 25th to the 29th of September. In addition to exhibiting, a total of 3
clinical and scientific posters will be presented at WUWHS which will highlight the clinical performance of several of the
Company's proprietary products.
“The WUWHS event brings together the thought leaders from almost every wound healing society around the world as a captive
audience for Covalon to showcase our impressive product portfolio,” said Brian Pedlar, Chief Executive Officer of Covalon. “In
addition to the opportunity for our team to interface one on one with an incredible collection of wound care clinicians, compelling
clinical and scientific studies that highlight the clinical advantages of our ColActive Plus product line that was recently
selected as the exclusive advanced collagen dressing for Saudi Arabian Ministry of Health facilities are being presented.”
WUWHS serves as a highly innovative and valuable event for medical professionals at all levels: physicians, nurses and all those
who work in contact with skin wounds on a daily basis. WUWHS 2016 offers an extensive scientific program including numerous
symposia, training sessions, workshops and focus sessions with leading international experts in the field of wound management.
“With Covalon’s ever expanding penetration into international markets, WUWHS is a great congress for us to reach key opinion
leaders from more than 40 countries” said John R. Hands, Executive Vice President. “From our CovaWound brand of advanced wound
management dressings to our patented ColActive bio-matrix technology designed to heal chronic wounds on limbs that may otherwise
face amputation, Covalon’s products are gaining global recognition as a better alternative to the legacy brands historically used
by advanced wound care clinicians.”
Covalon offers unique, patent protected infection management and advanced wound management solutions for the wound clinician.
Covalon’s CovaWound™ and ColActive® brands when used together have the ability to rapidly promote wound closure and healing in both
acute and chronic wounds, which has been referred to by experts as major threat to public health and the economy.1
Visit the Covalon Technologies Ltd. booth #61 from September 25-29 at the Fortezza da Basso Congress Center, Florence,
Italy.
About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the
world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies,
healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in
specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and
biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate",
"plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or
be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the
difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing
strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating
results and other risks, any of which could cause results, performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the
Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties
relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The
Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further
events or otherwise.
1 Sen, C. K., Gordillo, G. M., Roy, S., Kirsner, R., Lambert, L., Hunt, T. K., Gottrup, F., Gurtner, G. C. and
Longaker, M. T. (2009), Human skin wounds: A major and snowballing threat to public health and the economy. Wound Repair and
Regeneration, 17: 763–771. doi:10.1111/j.1524-475X.2009.00543.x
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20160926005125r1&sid=mstr2&distro=nx&lang=en)
Covalon Technologies Ltd.
Brian Pedlar, CEO
Email: bpedlar@covalon.com
Phone: 905.568.8400 x 233
Toll free: 1.877.711.6055
Web site: www.covalon.com
Twitter: @covalon
View source version on businesswire.com: http://www.businesswire.com/news/home/20160926005125/en/